Key Points
- Chidozie Ugwumba sold 25,040 Clene shares on April 17 at $6.43 for $161,007, cutting his stake by 6.46% to 362,729 shares (worth about $2.33M).
- Ugwumba has been liquidating stock repeatedly since January, disposing of roughly 111,550 shares across the trades disclosed, indicating sustained insider selling.
- Clene is a small-cap ($74.3M) clinical‑stage biopharma that recently reported an EPS miss (‑$0.88 vs. ‑$0.74) and carries an average analyst target of $33 with a "Moderate Buy" consensus.
Clene Inc. (NASDAQ:CLNN - Get Free Report) major shareholder Chidozie Ugwumba sold 6,374 shares of the business's stock in a transaction dated Wednesday, April 15th. The stock was sold at an average price of $6.48, for a total transaction of $41,303.52. Following the completion of the transaction, the insider directly owned 395,517 shares in the company, valued at $2,562,950.16. This trade represents a 1.59% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Major shareholders that own more than 10% of a company's stock are required to disclose their transactions with the SEC.
Chidozie Ugwumba also recently made the following trade(s):
- On Friday, April 17th, Chidozie Ugwumba sold 25,040 shares of Clene stock. The stock was sold at an average price of $6.43, for a total transaction of $161,007.20.
- On Thursday, April 16th, Chidozie Ugwumba sold 7,748 shares of Clene stock. The stock was sold at an average price of $6.40, for a total transaction of $49,587.20.
- On Thursday, April 2nd, Chidozie Ugwumba sold 24,925 shares of Clene stock. The stock was sold at an average price of $4.81, for a total transaction of $119,889.25.
- On Wednesday, April 1st, Chidozie Ugwumba sold 4,278 shares of Clene stock. The stock was sold at an average price of $4.97, for a total transaction of $21,261.66.
- On Tuesday, February 3rd, Chidozie Ugwumba sold 5,559 shares of Clene stock. The stock was sold at an average price of $4.10, for a total transaction of $22,791.90.
- On Monday, February 2nd, Chidozie Ugwumba sold 3,800 shares of Clene stock. The shares were sold at an average price of $4.04, for a total value of $15,352.00.
- On Friday, January 30th, Chidozie Ugwumba sold 5,686 shares of Clene stock. The shares were sold at an average price of $4.13, for a total value of $23,483.18.
- On Thursday, January 29th, Chidozie Ugwumba sold 15,284 shares of Clene stock. The shares were sold at an average price of $4.32, for a total value of $66,026.88.
- On Wednesday, January 28th, Chidozie Ugwumba sold 8,717 shares of Clene stock. The shares were sold at an average price of $4.91, for a total value of $42,800.47.
- On Tuesday, January 27th, Chidozie Ugwumba sold 4,139 shares of Clene stock. The shares were sold at an average price of $5.08, for a total value of $21,026.12.
Clene Stock Performance
Shares of Clene stock opened at $6.31 on Friday. Clene Inc. has a 52-week low of $2.28 and a 52-week high of $13.50. The stock's 50-day simple moving average is $5.36 and its 200 day simple moving average is $6.66. The stock has a market capitalization of $74.33 million, a P/E ratio of -2.43 and a beta of 0.62.
Clene (NASDAQ:CLNN - Get Free Report) last announced its quarterly earnings data on Thursday, March 12th. The company reported ($0.88) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.74) by ($0.14). The company had revenue of $0.08 million during the quarter, compared to analyst estimates of $0.03 million. Equities research analysts forecast that Clene Inc. will post -5.19 EPS for the current fiscal year.
Institutional Investors Weigh In On Clene
Hedge funds and other institutional investors have recently modified their holdings of the stock. Jones Financial Companies Lllp bought a new stake in shares of Clene during the third quarter valued at about $29,000. Jane Street Group LLC bought a new stake in shares of Clene during the second quarter valued at about $47,000. State Street Corp increased its position in shares of Clene by 138.4% during the fourth quarter. State Street Corp now owns 29,801 shares of the company's stock valued at $175,000 after buying an additional 17,300 shares during the period. PEAK6 LLC purchased a new position in shares of Clene during the fourth quarter worth about $294,000. Finally, Lunt Capital Management Inc. grew its holdings in shares of Clene by 2.5% during the third quarter. Lunt Capital Management Inc. now owns 52,260 shares of the company's stock worth $315,000 after purchasing an additional 1,250 shares in the last quarter. 23.28% of the stock is currently owned by institutional investors.
Analyst Upgrades and Downgrades
A number of equities research analysts recently issued reports on CLNN shares. D. Boral Capital restated a "buy" rating and issued a $23.00 price objective on shares of Clene in a research note on Thursday, March 12th. Weiss Ratings reiterated a "sell (d-)" rating on shares of Clene in a research report on Friday, January 9th. Finally, Canaccord Genuity Group reiterated a "buy" rating and set a $48.00 price target on shares of Clene in a research report on Friday, March 13th. Five research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, Clene presently has an average rating of "Moderate Buy" and a consensus price target of $33.00.
View Our Latest Research Report on CLNN
About Clene
(
Get Free Report)
Clene (NASDAQ: CLNN), also known as Clene Nanomedicine, is a clinical-stage biopharmaceutical company developing proprietary nanoparticle therapies aimed at treating neurodegenerative and demyelinating disorders. The company's flagship product, CNM-Au8, is a suspension of catalytic gold nanocrystals designed to enhance cellular energy metabolism, promote remyelination, and reduce oxidative stress. Clene's platform leverages the unique physicochemical properties of its nanoparticles to support neuronal health, with a focus on diseases that currently lack effective disease-modifying treatments.
Clene's lead candidate, CNM-Au8, is undergoing multiple clinical trials targeting conditions such as amyotrophic lateral sclerosis (ALS), Parkinson's disease, and multiple sclerosis (MS).
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
